Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow JNM on Twitter
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Subscribe to our RSS feeds
Meeting ReportMolecular Targeting Probes Track

Towards the Dual Click 18F-labeling of Antibodies

Johanna Steen, Christoph Denk, Kamilla Norregaard, Jesper Jorgensen, Raffaella Rossin, Dennis Svatunek, Patricia Edem, Marc Robillard, Andreas Kjaer, Jesper Kristensen, Hannes Mikula and Matthias Herth
Journal of Nuclear Medicine May 2018, 59 (supplement 1) 1144;
Johanna Steen
4Dept. of Clinical Physiology, Nuclear Medicine & PET Rigshospitalet, University Hospital Copenhagen Denmark
8Department of Drug Design and Pharmacology University of Copenhagen Copenhagen Denmark
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christoph Denk
9Institute for Applied Synthetic Chemistry Vienna University of Technology Vienna Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kamilla Norregaard
2Department of Clinical Physiology, Nuclear Medicin Rigshospitalet and University of Copenhagen Copenhagen N Denmark
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jesper Jorgensen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Raffaella Rossin
6Tagworks Pharmaceuticals Nijmegen Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dennis Svatunek
9Institute for Applied Synthetic Chemistry Vienna University of Technology Vienna Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Patricia Edem
7University of Copenhagen Copenhagen Denmark
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marc Robillard
5Tagworks Pharmaceuticals Eindhoven Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andreas Kjaer
1Rigshospitalet Copenhagen Denmark
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jesper Kristensen
7University of Copenhagen Copenhagen Denmark
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hannes Mikula
9Institute for Applied Synthetic Chemistry Vienna University of Technology Vienna Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matthias Herth
3Department of Clinical Physiology, Nuclear Medicine & PET and Cluster for Molecular Imaging Rigshospitalet, University Hospital Copenhagen Denmark
7University of Copenhagen Copenhagen Denmark
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
Loading

Abstract

1144

Objectives: Monoclonal antibodies (mAbs) are promising targeting-vectors for cancer diagnosis using nuclear molecular imaging techniques e.g. positron emission tomography (PET) due to their high affinity and specificity. However, their slow pharmacokinetics requires the use of long-lived radioisotopes in order to image their target accumulation. This results in high absorbed radiation doses for patients and a low imaging contrast.1,2 A pretargeted imaging approach, in which the targeting step is separated from the imaging step, circumvents these limitations since it enables the use of a short-lived radioisotope. This is achievable by using bioorthogonal click chemistry.3,4 Herein, we describe a pretargeted tumor imaging approach based on the inverse electron-demand Diels-Alder [4+2] cycloaddition (IEDDA) between various 18F-labeled 1,2,4,5-tetrazines and a mAb modified with trans-cyclooctene (TCO) (Figure 1). The sensitivity of the tetrazine-scaffold towards the basic conditions required for direct 18F-fluorination encouraged the use of an indirect labeling strategy by which a small library of 18F-tetrazines could be accessible for pretargeted imaging using PET.

Methods: [18F]Fluoride was produced via the (p,n)-reaction by bombardment of a [18O]H2O with a 11 MeV proton beam in a cyclotron. Analysis of 18F-fluorination reactions were performed by radio-HPLC and radio-TLC. Small animal PET/CT imaging was performed in naïve BALB/c mice for the preliminary biodistribution studies and in vivo stability assessments, and in nude BALB/c mice bearing tumor xenografts (LS174T) for the pretargeted tumor imaging experiments. Imaging was performed 1 h after tracer administration. Results: Tetrazine precursors bearing alkyne-moieties were synthesized and 18F-labeled with three different [18F]F-azide synthons via Cu-catalyzed azide-alkyne [3+2] cycloaddition (CuAAC) in non-decay corrected radiochemical yields between 2-22% for the CuAAC and 1-8% with regard to starting amount of [18F]F-. Promising candidates were selected based on biodistribution and stability for further evaluation in pretargeted experiments. For the pretargeted tumor imaging, TCO-functionalized CC49-mAbs targeting TAG-72 antigen were injected intravenously into tumor bearing mice 72 h prior to administration of high molar activity [18F]F-tetrazines. Preliminary results indicated a tumor uptake between 2-3% ID/g for the tetrazines evaluated until this date.

Conclusions: By using the CuAAC as an indirect labeling approach a small library of 18F- labeled tetrazines was available. Evaluation in pretargeted experiments is still ongoing. Future work is to develop a group of second generation tetrazines with more favorable pharmacokinetic profiles. Acknowledgements: The authors greatly acknowledge the H2020 project Click-it for financial support and the technical staff at the Department of Clinical Physiology, Nuclear Medicine & PET at Rigshospitalet, Denmark. References: 1. Rossin R. et al., Angew. Chem. Int. Ed. 2010; 49. 2. Keinänen O. et al., EJNMMI Res. 2017; 7:95. 3. Herth M. M. et al., Chem. Commun. 2013; 49. 4. Denk C. et al., Angew. Chem. Int. Ed. 2014; 53.

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint
Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 59, Issue supplement 1
May 1, 2018
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Towards the Dual Click 18F-labeling of Antibodies
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Towards the Dual Click 18F-labeling of Antibodies
Johanna Steen, Christoph Denk, Kamilla Norregaard, Jesper Jorgensen, Raffaella Rossin, Dennis Svatunek, Patricia Edem, Marc Robillard, Andreas Kjaer, Jesper Kristensen, Hannes Mikula, Matthias Herth
Journal of Nuclear Medicine May 2018, 59 (supplement 1) 1144;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Towards the Dual Click 18F-labeling of Antibodies
Johanna Steen, Christoph Denk, Kamilla Norregaard, Jesper Jorgensen, Raffaella Rossin, Dennis Svatunek, Patricia Edem, Marc Robillard, Andreas Kjaer, Jesper Kristensen, Hannes Mikula, Matthias Herth
Journal of Nuclear Medicine May 2018, 59 (supplement 1) 1144;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Figures & Data
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Molecular Targeting Probes Track

  • Synthesis and preliminary biological evaluation of a novel P2X7R radioligand [18F]IUR-1601
  • In vivo evaluation of [225Ac]Ac-DOTAZOL for α-therapy of bone metastases
  • Case study: Evaluating the new University of Florida hybrid pediatric phantoms and tissue weighting factors from ICRP Publication 103 for diagnostic dosimetry
Show more Molecular Targeting Probes Track

Preclinical Probes for Oncology Posters

  • Targeted molecular imaging of c-Met in NSCLC using 68Ga-labeled binding peptide
  • A Next Generation Theranostic PSMA Ligand for 64Cu and67Cu-Based Prostate Cancer Imaging and Therapy
  • A new PET imaging agent for monitoring HER2 status using Trastuzumab antibody conjugated with a novel 89 Zr-chelator.
Show more Preclinical Probes for Oncology Posters

Similar Articles

SNMMI

© 2023 Journal of Nuclear Medicine

Powered by HighWire